GC Cell Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
811
- Stock Symbol
-
144510
- Investments
-
6
- Share Price
-
$15.00
- (As of Tuesday Closing)
GC Cell General Information
Description
GC Cell Corp engages in the provision of anti-cancer immunotherapy. The company is developing an anticancer drug, which is in Phase II clinical trials; and stem cell treatment drugs. It also provides cell banking, sample inspection, clinical trial, and bio logistics services.
Contact Information
Website
www.gccell.comCorporate Office
- 107, Ihyeon-ro 30beon, Giheung
- Yongin, Gyeonggi 16924
- South Korea
Corporate Office
- 107, Ihyeon-ro 30beon, Giheung
- Yongin, Gyeonggi 16924
- South Korea
GC Cell Stock Performance
As of 15-Jul-2025, GC Cell’s stock price is $15.00. Its current market cap is $225M with 15M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $15.00 | $14.85 | $11.38 - $27.84 | $225M | 15M | 41K | -$3.92 |
GC Cell Financials Summary
As of 31-Mar-2025, GC Cell has a trailing 12-month revenue of $124M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 275,496 | 298,926 | 578,548 | 587,089 |
| Revenue | 123,962 | 127,856 | 143,443 | 182,739 |
| EBITDA | (49,469) | (42,687) | 8,243 | 40,032 |
| Net Income | (58,960) | (54,162) | (133) | 19,341 |
| Total Assets | 388,675 | 392,641 | 516,167 | 535,692 |
| Total Debt | 66,713 | 57,456 | 70,949 | 59,425 |
GC Cell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
GC Cell Patents
GC Cell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023355219-A1 | Chimeric antigen receptor targeting cd5 and immune cells expressing same | Pending | 05-Oct-2022 | ||
| AU-2023325154-A1 | Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car) | Pending | 17-Aug-2022 | ||
| EP-4572776-A2 | Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car) | Pending | 17-Aug-2022 | ||
| AU-2023248247-A1 | Method for introducing target gene into immune cells | Pending | 06-Apr-2022 | ||
| EP-4506460-A1 | Method for introducing target gene into immune cells | Pending | 06-Apr-2022 | C12N15/86 |
GC Cell Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
GC Cell Investments & Acquisitions (6)
GC Cell’s most recent deal was a Early Stage VC with Artiva for . The deal was made on 26-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Artiva | 26-Feb-2021 | Early Stage VC | Drug Discovery | ||
| Artiva | 26-Jun-2020 | Early Stage VC | Drug Discovery | ||
| Producer of drugs (GC Cell and Liminatus Pharma) | 24-Jul-2018 | Joint Venture | Drug Discovery | ||
| GC Lymphotec | 01-Apr-2018 | Merger/Acquisition | Other Healthcare Services | ||
| IlDong Holdings Company | 17-Jan-2014 | Secondary Transaction - Private | Holding Companies |
GC Cell ESG
Risk Overview
Risk Rating
Updated May, 11, 2024
21.26 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,697
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
GC Cell Exits (2)
GC Cell’s most recent exit was on 17-Jan-2014 from IlDong Holdings Company. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| IlDong Holdings Company | 17-Jan-2014 | Completed |
|
||
| IlDong Holdings Company | 01-Mar-2012 | Secondary Transaction - Private | Completed |
GC Cell Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| GC Lymphotec | Tokyo, Japan | 1999 |
GC Cell FAQs
-
When was GC Cell founded?
GC Cell was founded in 2011.
-
Where is GC Cell headquartered?
GC Cell is headquartered in Yongin, South Korea.
-
What is the size of GC Cell?
GC Cell has 811 total employees.
-
What industry is GC Cell in?
GC Cell’s primary industry is Biotechnology.
-
Is GC Cell a private or public company?
GC Cell is a Public company.
-
What is GC Cell’s stock symbol?
The ticker symbol for GC Cell is 144510.
-
What is the current stock price of GC Cell?
As of 15-Jul-2025 the stock price of GC Cell is $15.00.
-
What is the current market cap of GC Cell?
The current market capitalization of GC Cell is $225M.
-
What is GC Cell’s current revenue?
The trailing twelve month revenue for GC Cell is $124M.
-
What is GC Cell’s annual earnings per share (EPS)?
GC Cell’s EPS for 12 months was -$3.92.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
